Every year, millions of people go under general anesthesia without a second thought. For the vast majority, it's completely routine. But for a small, mostly undiagnosed slice of the population, specific anesthesia drugs trigger a runaway chain reaction inside their muscle cells — one that can spike body temperature past 104°F in minutes, and kill if it isn't caught immediately. The gene responsible is called RYR1, and the condition is malignant hyperthermia (MH).
What's Actually Happening Inside the Muscle
RYR1 encodes a calcium release channel in skeletal muscle called the ryanodine receptor. In a normal muscle contraction, this channel opens briefly to release calcium, then closes. In someone with a pathogenic RYR1 variant, specific anesthesia drugs — volatile agents like sevoflurane, desflurane, and isoflurane, or the muscle relaxant succinylcholine — cause the channel to jam open. Calcium floods the muscle cell uncontrollably.
What follows is a hypermetabolic crisis: sustained, rigid muscle contraction, a surge in carbon dioxide production, skyrocketing body temperature, breakdown of muscle tissue (rhabdomyolysis), and dangerous shifts in blood potassium and pH. Without rapid treatment, it progresses to cardiac arrest and multi-organ failure.
Recognizing It Fast Is the Entire Game
Malignant hyperthermia is treatable — there's an actual antidote, a drug called dantrolene, that stops the calcium leak and reverses the crisis. But it only works if it's given quickly. Anesthesiologists are trained to watch for the early warning signs constantly during surgery precisely because MH can escalate within minutes of drug exposure.
Why Nobody Finds Out Until It's Too Late — Usually
Unlike many genetic conditions, MH susceptibility can't be picked up on a routine physical, bloodwork, or family history alone — unless a relative has already had a documented episode or undergone confirmatory muscle biopsy testing (the in vitro contracture test, the historical gold standard). Most people with a pathogenic RYR1 variant have no idea until either they or a close relative has a reaction under anesthesia.
That's exactly the gap that genetic testing closes. RYR1 and the related CACNA1S and STAC3 genes are now recognized as the first-line genetic test for malignant hyperthermia susceptibility, and — critically — they're included on the American College of Medical Genetics and Genomics (ACMG) list of secondary findings that labs are expected to report back to you if found incidentally during whole genome sequencing, even if that wasn't why you were tested in the first place.
What Changes Once You Know Your Status
- You disclose it before every procedure. Dentists, surgeons, and anesthesiologists all need this information on your intake form — it's a permanent addition to your medical history, similar to a drug allergy.
- Anesthesia teams switch to a "trigger-free" protocol. Total intravenous anesthesia (TIVA) using drugs like propofol avoids the triggering agents entirely — MH-susceptible patients can still safely undergo surgery, they just need a different drug plan.
- Family members can be tested. Because MH susceptibility is autosomal dominant, first-degree relatives have a 50% chance of carrying the same variant — a finding in one family member is often the first clue that sends others to get tested.
| Without knowing RYR1 status | Knowing your RYR1 status |
|---|---|
| Standard anesthesia drugs used by default | Trigger-free anesthesia protocol used from the start |
| MH crisis recognized only after symptoms appear mid-surgery | Risk flagged before the first drug is given |
| Family members unaware they may share the same risk | At-risk relatives can be identified and tested proactively |
| Emergency response required if a reaction occurs | No reaction occurs — the trigger is simply avoided |
How Common Is a Confirmed Reaction, Actually?
Full-blown clinical MH reactions are rare in practice — estimates range from about 1 in 5,000 to 1 in 100,000 anesthesia administrations, depending on the population and drug combinations used. That gap between the 1-in-1,149 carrier frequency and the much rarer clinical reaction rate exists because most carriers simply haven't yet been exposed to the specific trigger combination in a way that produced a severe reaction, or reactions have gone unrecognized and unreported. The carrier frequency is the number that matters for testing purposes — it's the pool of people for whom a future exposure is a real, unpredictable risk.
Know Before You're on the Table
Dante Labs' whole genome sequencing reads RYR1, CACNA1S, and the full ACMG actionable gene panel — so an anesthesia risk like this shows up in your results instead of in an operating room.
Explore Whole Genome Sequencing →GENOME for 10% off